首页> 外文期刊>Cancer discovery. >Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15(+) Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy
【24h】

Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15(+) Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy

机译:单细胞RNA测序揭示了LRRC15(+)肌纤维细胞作为对癌症免疫疗法患者反应的决定因素的基质演进

获取原文
获取原文并翻译 | 示例
           

摘要

With only a fraction of patients responding to cancer immunotherapy, a better understanding of the entire tumor microenvironment is needed. Using single-cell transcriptomics, we chart the fibroblastic landscape during pancreatic ductal adenocarcinoma (PDAC) progression in animal models. We identify a population of carcinoma-associated fibroblasts (CAF) that are programmed by TGF beta and express the leucine-rich repeat containing 15 (LRRC15) protein. These LRRC15(+) CAFs surround tumor islets and are absent from normal pancreatic tissue. The presence of LRRC15(+) CAFs in human patients was confirmed in >80,000 single cells from 22 patients with PDAC as well as by using IHC on samples from 70 patients. Furthermore, immunotherapy clinical trials comprising more than 600 patients across six cancer types revealed elevated levels of the LRRC15(+) CAF signature correlated with poor response to anti-PD-L1 therapy. This work has important implications for targeting nonimmune elements of the tumor microenvironment to boost responses of patients with cancer to immune checkpoint blockade therapy.
机译:只有一小部分患者对癌症免疫疗法作出反应,需要更好地了解整个肿瘤微环境。使用单细胞转录组织,我们在动物模型中胰腺导管腺癌(PDAC)进展过程中的成纤维结构景观。我们鉴定由TGFβ编程的癌相关成纤维细胞(CAF)的群体,并表达含有15(LRRC15)蛋白的富含亮氨酸的重复。这些LRRC15(+)CAFS环绕着肿瘤胰岛,并且不存在正常的胰腺组织。从22例PDAC患者中,使用PDAC患者的> 80,000个单细胞的LRRC15(+)CAFS的存在,以及通过使用70例患者的样品进行IHC。此外,免疫疗法临床试验,患有600例患者患者患有600例患者,揭示了LRRC15(+)CAF签名水平的升高,与抗PD-L1疗法不良相关。这项工作对靶向肿瘤微环境的非免疫元素具有重要意义,使癌症患者的反应促进免疫检查点阻断治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号